Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 473

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 473
---
 Preferred Shares within 60 days of May 28, 2025, (iii) 700,337 NLS Common Shares issuable upon exercise of common warrants within 60 days of May 28, 2025, (iv) 809,920 NLS Common Shares issuable upon conversion of PPCs within 60 days of May 28, 2025, and (v) 192,308 NLS Common Shares issuable upon exercise of pre -fundedwarrants within 60 days of May 28, 2025. The common warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts Alpha from exercising that portion of the warrants that would result in Alpha and its affiliates owning, after exercise, a number of NLS Common Shares in excess of the beneficial ownership limitation. As a result, the number of NLS Common Shares reflected in the table owned by Alpha includes (a) any outstanding NLS Common Shares held by such shareholder, and (b) if any, the number of NLS Preferred Shares and warrants convertible into NLS Common Shares that the holder has the right to acquire within 60 days of May 28, 2025 without such holder or any of such holder’s affiliates beneficially owning more than the beneficial ownership limitation of 9.99%. The pre -fundedwarrants are subject to a beneficial ownership limitation of 4.99%. The address for Alpha is Lettstrasse 32, Vaduz 9490, Liechtenstein. Nicola Feuerstein, a Director of Alpha, holds voting and dispositive power over the securities held by Alpha. (9)Consists of (i) 189,012 NLS Common Shares, and (ii) 189,012 NLS Common Shares issuable upon exercise of common warrants exercisable within 60 days of May 28, 2025, subject to a beneficial ownership limitation of 9.99%. Revel Family Ltd. is controlled by Michel Revel, its sole equity owner, who holds voting and dispositive power over the securities. The address of Revel Family Ltd. is 52 HaNasi HaRishon Street, Rehovot, Israel, 7630242. (10)Consists of (i) 58,730 NLS Common Shares held by BIOTECHNOLOGY VALUE FUND II, L.P., (ii) 6,677 NLS Common Shares held by BIOTECHNOLOGY VALUE TRADING FUND OS